Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Recent studies from Nicholas Copernicus University, Medical Department add new data to acute myeloid leukemia
March 30th, 2008
"Bortezomib is an inhibitor of proteasome and NF-kappa B, with activity in various solid tumors and hematological malignancies. The aim of the study was the analysis of in vitro drug resistance to bortezomib and other anticancer drugs in de novo and relapsed adult acute myeloid leukemia (AML)," scientists writing in the journal Anticancer Research report. "The leukemic cells of 46 adult patients with AML were tested for the in vitro drug resistance profile. The group included 20 de novo and 26 relapsed AML patients, among whom, 12 relapsed after allogeneic hematopoietic stem cell transplantation (HSCT) and 4 after autologous HSCT The MTT assay was performed for...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-30)
|
